Nigeria’s pharmaceutical sector is structurally import dependent, particularly for Active Pharmaceutical Ingredients (APIs) and Excipients, over 90% of which are sourced externally. Consequently, the sector has been historically exposed to foreign exchange volatility and global supply disruptions. This is in stark contrast to the country’s status as one of Africa’s largest economies as Nigeria serves as a consumption market, with limited export competitiveness compared to peers such as South Africa and Egypt.
Several structural headwinds constrain the sector, apart from its high import-dependence and strong exposure to exchange rate volatility. Logistics and infrastructure deficits -particularly port congestion, weak road networks, and severe cold-chain limitations- extend lead times and raise operating costs. Also, access to affordable capital is constrained by high interest rates, limiting the ability of firms to scale, modernize, and compete globally. In addition, the limited domestic production of APIs and excipients reinforces supply vulnerability, while low adoption of digital technologies restricts supply chain visibility and efficiency. The continued prevalence of counterfeit medicines poses both a public health and commercial risk, and talent shortages, especially in digitally enabled and regulatorycompliant supply chain roles, further constrain industry development. But the sector is now undergoing a transformational shift, supported by policy reforms, increasing local manufacturing capacity, and strong underlying demand fundamentals. On the supply side, regulatory reforms are increasingly reshaping incentives that are redefining the landscape.
Policies such as the “5+5” localisation directive, the expansion of contract manufacturing, the introduction of Medipool as a national group purchasing organisation, and the rollout of mandatory product traceability systems are collectively improving market structure, quality assurance, and investment attractiveness. Global case studies, particularly from India and Bangladesh, demonstrate that sustained success in pharmaceutical industrialisation is driven by deliberate and coordinated policy action, including, targeted protection of domestic markets, and incentives tied directly to production and export performance, and the strategic use of intellectual property frameworks. These experiences reinforce the importance of long-term commitment and policy consistency in building globally competitive pharmaceutical ecosystems.
To fully unlock its potential, Nigeria must accelerate its transition from an import-dependent system to a resilient and competitive manufacturing hub. Central to this transformation is the localisation of API production as a matter of national health and economic security, alongside stronger alignment between production and aggregated demand platforms such as Medipool. At the same time, investments in modern cold-chain infrastructure, particularly solar-powered systems, will enhance distribution reliability, while a sequenced rollout of digital supply chain technologies can significantly improve efficiency, forecasting, and decision-making. These priorities will help to define a clear pathway not only for strengthening domestic capacity but for positioning Nigeria as a credible pharmaceutical manufacturing and export leader in the region.
